Celltrion

Evolution step-up growth trajectory upward trajectory
Pharma

How biosimilar developers are embracing next phase of US market

Although the so-called biosimilar ‘void’ could pose challenges to upcoming biosimilar availability, the opportunity it presents is also immense.
Asia

China's BCI nod, AZ, Astellas—Fierce Pharma Asia

Mar 20, 2026 8:00am
Celltrion

Celltrion earmarks $478M to bolster US manufacturing capacity

Nov 19, 2025 11:31am
newspaper

Lilly-XtalPi, Celltrion, Illumina in China—Fierce Pharma Asia

Nov 7, 2025 9:41am
partnership collaboration legal document

Regeneron, Celltrion shake hands on Eylea biosimilar settlement

Oct 22, 2025 8:15am
newspaper

Celltrion buy, Rexulti CRL, Glenmark-Hengrui—Fierce Pharma Asia

Sep 26, 2025 10:00am